Jin L, Briggs S L, Chandrasekhar S, Chirgadze N Y, Clawson D K, Schevitz R W, Smiley D L, Tashjian A H, Zhang F
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana 46285, USA.
J Biol Chem. 2000 Sep 1;275(35):27238-44. doi: 10.1074/jbc.M001134200.
The N-terminal fragment 1-34 of parathyroid hormone (PTH), administered intermittently, results in increased bone formation in patients with osteoporosis. PTH and a related molecule, parathyroid hormone-related peptide (PTHrP), act on cells via a common PTH/PTHrP receptor. To define more precisely the ligand-receptor interactions, we have crystallized human PTH (hPTH)-(1-34) and determined the structure to 0.9-A resolution. hPTH-(1-34) crystallizes as a slightly bent, long helical dimer. Analysis reveals that the extended helical conformation of hPTH-(1-34) is the likely bioactive conformation. We have developed molecular models for the interaction of hPTH-(1-34) and hPTHrP-(1-34) with the PTH/PTHrP receptor. A receptor binding pocket for the N terminus of hPTH-(1-34) and a hydrophobic interface with the receptor for the C terminus of hPTH-(1-34) are proposed.
甲状旁腺激素(PTH)的N端片段1 - 34间歇性给药可使骨质疏松症患者的骨形成增加。PTH和一种相关分子,甲状旁腺激素相关肽(PTHrP),通过共同的PTH/PTHrP受体作用于细胞。为了更精确地定义配体 - 受体相互作用,我们已使人类PTH(hPTH) - (1 - 34)结晶,并确定其结构分辨率为0.9埃。hPTH - (1 - 34)结晶为轻微弯曲的长螺旋二聚体。分析表明,hPTH - (1 - 34)的延伸螺旋构象可能是生物活性构象。我们已开发出hPTH - (1 - 34)和hPTHrP - (1 - 34)与PTH/PTHrP受体相互作用的分子模型。提出了一个针对hPTH - (1 - 34)N端的受体结合口袋以及一个针对hPTH - (1 - 34)C端与受体的疏水界面。